ISM0676 / Insilico Medicine - LARVOL DELTA

Insilico Medicine…announces the nomination of ISM0676 as a Preclinical Candidate (PCC) targeting the Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR). Developed as an orally bioavailable small molecule antagonist, ISM0676 is designed for the treatment of obesity and associated diseases, including Type 2 diabetes… (PRNewswire) - "Preclinical studies have highlighted up to 31.3% body weight loss in diet-induced obese (DIO) humanized GIPR mice when co-administered with semaglutide. ISM0676 also demonstrated excellent in vivo metabolic stability, low drug-drug interaction risk, favorable safety profiles, and low predicted human efficacious dose, supporting future development."

Pipeline update • Preclinical • Obesity • Type 2 Diabetes Mellitus